BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Announces Q3 Growth of DetermaRx(TM) Physician Adoption, Testing Volume

November 2, 2020 12:12:55

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, recently provided an update on DetermaRx’s global growth and adoption. According to the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high risk of recurrence, despite ostensibly curative surgery, who may benefit from the addition of chemotherapy. Since its January commercial launch in the U.S., DetermaRx has begun to be reimbursed by Medicare and multiple private payers and has seen rapid adoption across 67 hospitals. “We are encouraged by the increasing quarter-over-quarter growth of DetermaRx,” Padma Sundar, head of commercial at Oncocyte, said in the press release. “Our rapid growth is taking place across all important metrics, such as test volume, reorder rate, inclusion in hospital ordering systems, and test adoption at premiere community practices as well as prestigious National Cancer Institute (“NCI”) designated cancer centers and National Comprehensive Network Cancer (“NCCN”) centers. We believe the rapid adoption of DetermaRx reflects the significant clinical need for this test, which is the only test currently available to drive critical treatment decisions for early-stage lung cancer patients who may be at risk for recurrence. Our compelling new prospective data demonstrates that treatment informed by DetermaRx significantly improves lung cancer patient survival, and we believe this test could be practice-changing, potentially guiding the use of not only chemotherapy but also the use of targeted therapies in the future.”

To view the full press release, visit

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The company’s proprietary tests and pharmaceutical company services aim to save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. Oncocyte’s tests and services present multiple opportunities to advance cancer care while driving the growth of its revenue. The company recently launched DetermaRx(TM), a treatment stratification test to identify early-stage lung cancer patients who are at high risk for cancer recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO(TM), a gene expression test that identifies patients who are more likely to respond to checkpoint inhibitor immunotherapies. The company also plans to launch Therasure(TM)-CNI MONITOR, a blood-based immune therapy monitoring test. Oncocyte’s pharmaceutical company services help pharmaceutical companies to develop new cancer treatments, many of which may be linked to Oncocyte’s diagnostic tests. For more information about the company, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork